Pesquisas alternativas:
disease living » disease moving (Expandir a Pesquisa), disease leading (Expandir a Pesquisa), disease long (Expandir a Pesquisa)
doses develop » loss develop (Expandir a Pesquisa), posters develop (Expandir a Pesquisa), models develop (Expandir a Pesquisa)
develop them » develop type (Expandir a Pesquisa), develop age (Expandir a Pesquisa)
living thle2 » living three (Expandir a Pesquisa), living tree (Expandir a Pesquisa), living trees (Expandir a Pesquisa)
drug doses » drug dose (Expandir a Pesquisa), drug disease (Expandir a Pesquisa)
drug noise » drug naive (Expandir a Pesquisa), drug nurse (Expandir a Pesquisa), during noise (Expandir a Pesquisa)
level ther » level theory (Expandir a Pesquisa), level rather (Expandir a Pesquisa), levels other (Expandir a Pesquisa)
disease living » disease moving (Expandir a Pesquisa), disease leading (Expandir a Pesquisa), disease long (Expandir a Pesquisa)
doses develop » loss develop (Expandir a Pesquisa), posters develop (Expandir a Pesquisa), models develop (Expandir a Pesquisa)
develop them » develop type (Expandir a Pesquisa), develop age (Expandir a Pesquisa)
living thle2 » living three (Expandir a Pesquisa), living tree (Expandir a Pesquisa), living trees (Expandir a Pesquisa)
drug doses » drug dose (Expandir a Pesquisa), drug disease (Expandir a Pesquisa)
drug noise » drug naive (Expandir a Pesquisa), drug nurse (Expandir a Pesquisa), during noise (Expandir a Pesquisa)
level ther » level theory (Expandir a Pesquisa), level rather (Expandir a Pesquisa), levels other (Expandir a Pesquisa)
1
Por Gisslinger, Heinz, Zagrijtschuk, Oleh, Buxhofer-Ausch, Veronika, Thaler, Josef, Schloegl, Ernst, Gastl, Guenther A., Wolf, Dominik, Kralovics, Robert, Gisslinger, Bettina, Strecker, Karin, Egle, Alexander, Melchardt, Thomas, Burgstaller, Sonja, Willenbacher, Ella, Schalling, Martin, Them, Nicole C., Kadlecova, Pavla, Klade, Christoph, Greil, Richard
Publicado no Blood (2015)
“... and safety of ropeginterferon alfa-2b and support the development of the drug in a randomized phase 3...”Publicado no Blood (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
2
Por Hansen, Aaron R., Cook, Natalie, Ricci, M. Stacey, Razak, Albiruni, Le Tourneau, Christophe, McKeever, Kathleen, Roskos, Lorin, Dixit, Rakesh, Siu, Lillian L., Hinrichs, Mary Jane
Publicado no Oncologist (2015)
Assuntos:
“...New Drug Development and Clinical Pharmacology...”Publicado no Oncologist (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
3
4
Por Tácio de Mendonça Lima, Millena Padela da Silva, Luan Donato Silva Luz, Thais Cristina Amorim Estevão Soares, Etielle Silvestre Dantas, Gabriela Felix Teixeira, Rafael Henrique de Souza Costa, Sérgio Henrique Monte Santo Andrade
Publicado em 2022-03-01
Assuntos:
“...Drug dosage calculation...”Publicado em 2022-03-01
Obter o texto integral
Artigo
5
Por Yoshida, Mari, Reyes, Sabrina Galiñanes, Tsuda, Soichiro, Horinouchi, Takaaki, Furusawa, Chikara, Cronin, Leroy
Publicado no Nat Commun (2017)
“... develop a simple deterministic model, which allows us to predict the fate of multi-drug evolution...”Publicado no Nat Commun (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
6
“... thiethylperazine (6/13 v 2/6) and at least one non-steroidal anti-inflammatory drug (10/13 v 2/6), whereas a...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
7
8
Por Bates, Susan E., Berry, Donald A., Balasubramaniam, Sanjeeve, Bailey, Stuart, Rubin, Eric H., LoRusso, Patricia M.
Publicado no Clin Cancer Res (2015)
“.... The FDA is involved in the drug approval process from points early in development, and has accepted...”Publicado no Clin Cancer Res (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
9
Por Yu. M. Gomon, A. A. Kurylev, A. S. Kolbin, M. A. Proskurin, I. G. Ivanov, S. V. Sidorenko, M. A. Arepieva, A. V. Sokolov
Publicado em 2018-10-01
Assuntos:
“...antimicrobial drugs...”Publicado em 2018-10-01
Obter o texto integral
Artigo
10
Por Cooper, Jason P, Reynolds, C Patrick, Cho, Hwangeui, Kang, Min H
Publicado no Exp Biol Med (Maywood) (2017)
“... or in combination with other drugs. IMPACT STATEMENT: One of the critical components in drug development...”Publicado no Exp Biol Med (Maywood) (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
11
Por Bremer, Paul T., Kimishima, Atsushi, Schlosburg, Joel E., Zhou, Bin, Collins, Karen C., Janda, Kim D.
Publicado no Angew Chem Int Ed Engl (2016)
“.... The synthetic nature of fentanyl has enabled the creation of dangerous ‘designer drug’ analogues that escape...”Publicado no Angew Chem Int Ed Engl (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
12
“...There is an apparent need to improve the speed and efficiency of oncological drug development...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
13
“... of incubation. To get an idea about the extent of the teratogenic effect of this drug on the development retina...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
14
“... or chronically has made them ubiquitous in drug discovery and basic research. The recent availability of iPRECIO...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
15
Por Gomberg-Maitland, M, Maitland, ML, Barst, RJ, Sugeng, L, Coslet, S, Perrino, TJ, Bond, L, LaCouture, ME, Archer, SL, Ratain, MJ
Publicado em 2009
“.... The adaptation of new drugs across these disease populations warrants a structured approach. This study was a 16...”Publicado em 2009
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
16
“...For rapid anti-tuberculosis (TB) drug development in vitro pharmacokinetic/pharmacodynamic (PK/PD...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
17
Por Larson, Charles P., Sauvé, Laura, Senkungu, Jude Kimbowa, Arifeen, Shams El, Brant, Rollin
Publicado no J Pediatr Pharmacol Ther (2015)
“... therapeutic dose across the 4 weight bands for each of the 6 drugs tested. None of the drugs tested would...”Publicado no J Pediatr Pharmacol Ther (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
18
“... the method to the 3,394 patients in the cohort, we identified AEs linked with a drug in 2,402 patients (70.8...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
19
20
“... drugs were able to cross the BBB. Lixisenatide crossed the BBB at all doses tested (2.5, 25, or 250 nmol...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo